- Clone:
- REAL218
- Type of antibody:
- Releasable antibodies, Primary antibodies, Recombinant antibodies
- Applications:
- FC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for CD105 Antibody, anti-human, REAlease®
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
Overlay histogram showing flow cytometric analysis of CD105 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD105-PE, clone (REAL218). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD105 (REAL218). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REAL218 is an antibody fragment derived from the full CD105 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL218 recognizes the CD105 antigen, also known as endoglin, which serves as a receptor for the growth and differentiation factors TGF-β1 and TGF-β3. An epitope of CD105 is recognized by the SH-2 antibody, which was raised against human mesenchymal stromal cells (MSC) that show mesodermal differentiation capacity. Therefore, it can be used for studies on mesengenesis. CD105 is also expressed on mature endothelial cells and on some leukemic cells of B lymphoid and myeloid origin.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
ENG, END, HHT1, ORW1, Endoglin
Technical specifications
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Bellón, T. et al. (1993) Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23 (9): 2340-2345
- Barry, F. P. et al. (1999) The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun. 265: 134-139
- Majumdar, M. K. et al. (2000) Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J. Cell. Physiol. 185: 98-106